David Hung, M.D.
Principal executive officer pay for David Hung, M.D., by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Nuvation Bio Inc. (NUVB) FY2022–FY2025
Aligned: paid up as stock roseCAP $1,913,399→$27,829,744 while $100 invested went $16.41→$76.58
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2022 | $8.1M | $1.9M |
| FY2023 | $4.3M | $2.8M |
| FY2024 | $3.7M | $6.5M |
| FY2025 | $3.9M | $27.8M |
The company's "$100 invested" index ran $16.41 at FY2022 → $76.58 by FY2025 — an annualized return of 67.1%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 67.1%/yr at NUVB ( FY2022–FY2025). See the CEO track-record ranking for context.